维持性透析的终末期肾衰竭患者中头孢替坦的药代动力学

Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.

作者信息

Browning M J, Holt H A, White L O, Chapman S T, Banks R A, Reeves D S, Yates R A

出版信息

J Antimicrob Chemother. 1986 Jul;18(1):103-6. doi: 10.1093/jac/18.1.103.

DOI:10.1093/jac/18.1.103

Abstract

The pharmacokinetics of a single intravenous dose of cefotetan were studied in 17 volunteer patients with end-stage renal failure, requiring intermittent haemodialysis in 12 cases or undergoing continuous ambulatory peritoneal dialysis in 5 cases. Between haemodialysis the mean plasma elimination half life was 20.4 h (S.E.M. +/- 2.1). This decreased to 7.5 h (S.E.M. +/- 0.6) during haemodialysis. In patients treated by continuous ambulatory peritoneal dialysis the mean plasma elimination half life was 15.5 h (S.E.M. +/- 1.9). Small amounts of cefotetan (5-9% of the administered dose) were recovered in the peritoneal dialysates removed over the 24 h following the dose.

摘要

对17例终末期肾衰竭志愿者患者进行了研究，观察单次静脉注射头孢替坦后的药代动力学。其中12例患者需间歇性血液透析，5例患者接受持续性非卧床腹膜透析。血液透析期间，血浆消除半衰期均值为20.4小时（标准误±2.1）。血液透析时该值降至7.5小时（标准误±0.6）。接受持续性非卧床腹膜透析治疗的患者，血浆消除半衰期均值为15.5小时（标准误±1.9）。给药后24小时内收集的腹膜透析液中回收了少量头孢替坦（占给药剂量的5-9%）。